title: Effects of fish oil rich in polyunsaturated fatty acids on hyperlipidemia of hemodialysis patients.
abstract: Hemodialysis (HD) patients have a high incidence of hyperlipidemia. Hypertriglyceridemia is the most frequent abnormality encountered. It results mainly from a defect in the degradation of triglycerides. The aim of this study was to evaluate the efficacy of a fish oil (Max-EPA) rich in polyunsaturated fatty acids (PUFA), such as eicosapantenoic acid (EPA), on lipid abnormalities of hemodialysis patients. Thirteen hyperlipidemic HD patients were investigated (7 males, 6 females; mean age 57 years; mean duration of HD 72 months). None were diabetic or treated with antihypertensive drugs. All patients had hypertriglyceridemia (greater than 200 mg/dl) and an increase (greater than 1) in the ratio of serum apolipoprotein B to serum apolipoprotein A1 (ApoB/ApoA1). They received for one month, 6 g/day of Max-EPA providing 1 g of EPA. After treatment, serum triglyceride levels fell by 38% from 231 +/- 40 (SD) mg/dl to 140 +/- 38 mg/dl (P less than 0.01). Total cholesterol did not change significantly (before therapy 241 +/- 33 mg/dl, after therapy 249 +/- 38 mg/dl). Apolipoprotein A1 levels (116 +/- 17 mg/dl) were not modified after therapy, 117 +/- 11 mg/dl. Apolipoprotein B decreased significantly from 182 +/- 26 mg/dl to 150 +/- 21 mg/dl after treatment (P less than 0.01). The ApoB/ApoA1 ratio showed a significant decrease from 1.56 +/- 0.26 to 1.3 +/- 0.16 after therapy (P less than 0.01). Also, the greatest reductions were found in the patients who had both the highest serum triglyceride levels and the highest ApoB/ApoA1 ratios. No side effects were observed.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Nephrology and Hemodialysis Center, Dunkerque General Hospital, Lille, France.
authors.forename: R
authors.initials: R
authors.lastname: Azar
authors.forename: F
authors.initials: F
authors.lastname: Dequiedt
authors.forename: J
authors.initials: J
authors.lastname: Awada
authors.forename: P
authors.initials: P
authors.lastname: Dequiedt
authors.forename: A
authors.initials: A
authors.lastname: Tacquet
mesh_terms: D000328:Adult; D000368:Aged; D016632:Apolipoprotein A-I; D001054:Apolipoproteins A / Q000097:blood; D001055:Apolipoproteins B / Q000097:blood; D005231:Fatty Acids, Unsaturated / Q000627:therapeutic use*; D005260:Female; D005395:Fish Oils / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000209:etiology / Q000628:therapy*; D007676:Kidney Failure, Chronic / Q000150:complications; D008075:Lipoproteins, HDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D014280:Triglycerides / Q000097:blood
chemical_list: D016632:Apolipoprotein A-I; D001054:Apolipoproteins A; D001055:Apolipoproteins B; D005231:Fatty Acids, Unsaturated; D005395:Fish Oils; D008075:Lipoproteins, HDL; D014280:Triglycerides